NNNN Quote, Financials, Valuation and Earnings

CureVac NV has a net margin of -- compared to Anbio Biotechnology's net margin of -5832.47%. Anbio Biotechnology's return on equity of -- beat CureVac NV's return on equity of 20.55%.

Anbio Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand CureVac NV has an analysts' consensus of $5.31 which suggests that it could grow by 3.16%. Given that CureVac NV has higher upside potential than Anbio Biotechnology, analysts believe CureVac NV is more attractive than Anbio Biotechnology.

Anbio Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CureVac NV has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.063%.

Anbio Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CureVac NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anbio Biotechnology pays -- of its earnings as a dividend. CureVac NV pays out -- of its earnings as a dividend.

Anbio Biotechnology quarterly revenues are --, which are smaller than CureVac NV quarterly revenues of $63.3M. Anbio Biotechnology's net income of -- is lower than CureVac NV's net income of $319.3M. Notably, Anbio Biotechnology's price-to-earnings ratio is -- while CureVac NV's PE ratio is 7.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anbio Biotechnology is 164.94x versus 14.33x for CureVac NV. Usually stocks with elevated PS ratios are considered overvalued.

Evotec SE has a net margin of -- compared to Anbio Biotechnology's net margin of -26.29%. Anbio Biotechnology's return on equity of -- beat Evotec SE's return on equity of -17.7%.

Anbio Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand Evotec SE has an analysts' consensus of $5.4436 which suggests that it could grow by 70.76%. Given that Evotec SE has higher upside potential than Anbio Biotechnology, analysts believe Evotec SE is more attractive than Anbio Biotechnology.

Anbio Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Evotec SE has a beta of 1.821, suggesting its more volatile than the S&P 500 by 82.079%.

Anbio Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evotec SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anbio Biotechnology pays -- of its earnings as a dividend. Evotec SE pays out -- of its earnings as a dividend.

Anbio Biotechnology quarterly revenues are --, which are smaller than Evotec SE quarterly revenues of $191.5M. Anbio Biotechnology's net income of -- is lower than Evotec SE's net income of -$50.3M. Notably, Anbio Biotechnology's price-to-earnings ratio is -- while Evotec SE's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anbio Biotechnology is 164.94x versus 1.37x for Evotec SE. Usually stocks with elevated PS ratios are considered overvalued.

InflaRx NV has a net margin of -- compared to Anbio Biotechnology's net margin of -51538.49%. Anbio Biotechnology's return on equity of -- beat InflaRx NV's return on equity of -82.01%.

Anbio Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand InflaRx NV has an analysts' consensus of $11.64 which suggests that it could grow by 1041.22%. Given that InflaRx NV has higher upside potential than Anbio Biotechnology, analysts believe InflaRx NV is more attractive than Anbio Biotechnology.

Anbio Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.459, suggesting its more volatile than the S&P 500 by 45.896%.

Anbio Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anbio Biotechnology pays -- of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend.

Anbio Biotechnology quarterly revenues are --, which are smaller than InflaRx NV quarterly revenues of $27.8K. Anbio Biotechnology's net income of -- is lower than InflaRx NV's net income of -$14.3M. Notably, Anbio Biotechnology's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anbio Biotechnology is 164.94x versus 315.16x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.

Immatics NV has a net margin of -- compared to Anbio Biotechnology's net margin of -974.45%. Anbio Biotechnology's return on equity of -- beat Immatics NV's return on equity of -25.21%.

Anbio Biotechnology has a consensus price target of --, signalling downside risk potential of --. On the other hand Immatics NV has an analysts' consensus of $18.63 which suggests that it could grow by 80.13%. Given that Immatics NV has higher upside potential than Anbio Biotechnology, analysts believe Immatics NV is more attractive than Anbio Biotechnology.

Anbio Biotechnology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.134%.

Anbio Biotechnology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Anbio Biotechnology pays -- of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend.

Anbio Biotechnology quarterly revenues are --, which are smaller than Immatics NV quarterly revenues of $6.1M. Anbio Biotechnology's net income of -- is lower than Immatics NV's net income of -$59.1M. Notably, Anbio Biotechnology's price-to-earnings ratio is -- while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Anbio Biotechnology is 164.94x versus 13.81x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.